Seres Therapeutics
MCRB
Seres Therapeutics (MCRB) earnings history
Most recent quarter
- Fiscal period
- Q4 2025
- Period end
- Dec 31, 2025
- EPS actual
- −$1.78
- EPS estimate
- −$2.11
- EPS surprise
- +15.64%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Mar 12, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2025 | Mar 12, 2026 | −$2.11 | −$1.78 | +15.64% | $0.00 | SEC |
| Q3 2025 | Nov 5, 2025 | $0.46 | $0.94 | +105.82% | $351,000.00 | SEC |
| Q2 2025 | Aug 6, 2025 | −$2.49 | −$2.27 | +8.84% | $0.00 | SEC |
| Q1 2025 | May 7, 2025 | $0.10 | $3.75 | +3576.47% | $0.00 | SEC |
| Q4 2024 | Mar 13, 2025 | −$3.93 | −$1.80 | +54.20% | $0.00 | SEC |
| Q3 2024 | Nov 13, 2024 | −$1.55 | $11.60 | +848.10% | $0.00 | SEC |
| Q2 2024 | Aug 13, 2024 | −$5.48 | −$4.40 | +19.73% | $0.00 | SEC |
| Q1 2024 | May 8, 2024 | −$6.83 | −$5.40 | +20.98% | $0.00 | SEC |
| Q4 2023 | Mar 5, 2024 | −$9.93 | −$6.20 | +37.58% | $65,000.00 | SEC |
| Q3 2023 | Nov 2, 2023 | −$10.03 | −$7.40 | +26.21% | $310,000.00 | SEC |
| Q2 2023 | Aug 8, 2023 | $10.69 | $7.20 | −32.64% | $126.5M | SEC |
| Q1 2023 | May 9, 2023 | −$11.00 | −$11.40 | −3.64% | −$522,000.00 | SEC |
| Q4 2022 | Mar 7, 2023 | −$9.10 | −$10.20 | −12.09% | $974,000.00 | SEC |
| Q3 2022 | Nov 2, 2022 | −$9.38 | −$9.80 | −4.53% | $3.4M | SEC |
| Q2 2022 | Aug 3, 2022 | −$11.93 | −$14.00 | −17.40% | $1.2M | SEC |
| Q1 2022 | May 4, 2022 | −$10.48 | −$12.20 | −16.47% | $1.5M | SEC |
| Q4 2021 | Mar 1, 2022 | −$8.73 | −$10.40 | −19.08% | $7.2M | SEC |
| Q3 2021 | Nov 10, 2021 | −$1.09 | $14.40 | +1422.44% | $126.7M | SEC |
| Q2 2021 | Aug 3, 2021 | −$7.40 | −$10.60 | −43.24% | $5.3M | SEC |
| Q1 2021 | May 4, 2021 | −$6.20 | −$7.80 | −25.81% | $5.7M | SEC |
Quarterly revenue
Frequently asked questions
When did Seres Therapeutics (MCRB) last report earnings?
Seres Therapeutics last reported on Mar 12, 2026, covering fiscal Q4 2025.
Did MCRB beat earnings estimates?
Yes. Seres Therapeutics reported EPS of −$1.78 for Q4 2025 against a −$2.11 estimate — a 15.64% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.